Home/NervGen Pharma/Brian Bayley
BB

Brian Bayley

Director

NervGen Pharma

NervGen Pharma Pipeline

DrugIndicationPhase
NVG-291Chronic & Subacute Spinal Cord InjuryPhase 1b/2a
NVG-300Undisclosed Neurodegenerative IndicationsDiscovery